As people suffering from neglected diseases do not represent a lucrative market for pharmaceutical companies, the incentives to invest in research and development are lacking for these diseases [REF].
To overcome the lack of commercial research into drug development, PDPs can apply "delinkage" principles that aim to separate the cost of research and development from the price of products.